ArticleFrontiers in oncology2025
The modified Glasgow prognostic score serves as a robust predictor of unplanned readmission and 1-year mortality in lung cancer patients receiving immune checkpoint inhibitors.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The modified Glasgow Prognostic Score (mGPS), which reflects the degree of systemic inflammation and nutritional status, is associated with prognosis in various common malignancies. However, its association with 30-day unplanned readmission and 1-year mortality in stage III-IV lung cancer (LC) patients remains unvalidated. This study aimed to evaluate the prognostic value of mGPS in stage III-IV LC patients receiving immune checkpoint inhibitors (ICIs). Methods: In this retrospective study, 209 patients diagnosed with stage III-IV LC who underwent ICI therapy between January 2023 and May 2024 were included. Patients were stratified based on mGPS scores into three risk categories: low-risk (0 points), intermediate-risk (1 point), and high-risk (2 points). Kaplan-Meier analyses, multivariate Cox proportional hazard regression, and subgroup analyses were employed to assess primary outcomes. Results: Among the enrolled patients, the rates of 30-day unplanned readmission and 1-year mortality were 35.4% (74/209) and 11.0% (23/209), respectively. Kaplan-Meier analysis indicated significantly elevated cumulative incidences of 30-day unplanned readmission and 1-year mortality in the high-risk group relative to intermediate- and low-risk groups (log-rank Conclusion: Higher mGPS scores significantly correlate with elevated risks of both 30-day unplanned readmission and 1-year mortality among LC patients receiving ICI therapy. Routine mGPS monitoring may warrants further evaluation in prospective multicenter validation studies to inform prophylactic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.